Trials / Completed
CompletedNCT00316420
Gemcitabine and Capecitabine in Patients With Advanced Pancreatic Cancer
Phase I Trial of Gemcitabine and Capecitabine (Xeloda) in Patients With Advanced Pancreatic Carcinoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Swedish Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the effectiveness and safety of the drug combination of gemcitabine and capecitabine (Xeloda) in patients with advanced pancreatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Capecitabine (Xeloda) | 650 mg/m2 po bid Days 1-14 750 mg/m2 po bid Days 1-14 850 mg/m2 po bid Days 1-14 950 mg/m2 po bid Days 1-14 |
| DRUG | Gemcitabine | 750 mg/m2 IV Days 1 \& 8 q 21 days |
Timeline
- Start date
- 2003-12-01
- Primary completion
- 2009-02-01
- Completion
- 2009-08-01
- First posted
- 2006-04-20
- Last updated
- 2010-03-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00316420. Inclusion in this directory is not an endorsement.